By Mill Chart
Last update: Jul 30, 2025
Wave Life Sciences Ltd (NASDAQ:WVE) reported its second-quarter 2025 financial results, missing analyst revenue estimates but showing a narrower-than-expected loss per share. The company posted revenue of $8.7 million, falling short of the consensus estimate of $11.42 million. Meanwhile, its reported loss per share of $0.31 was slightly better than the anticipated $0.29 loss.
The company highlighted progress in its RestorAATion-2 study for WVE-006, its leading RNA-editing candidate targeting Alpha-1 antitrypsin deficiency (AATD). Key developments include:
The pre-market uptick indicates that investors may be focusing more on the clinical progress rather than the revenue miss. With no explicit financial guidance provided in the press release, the market reaction appears driven by optimism around WVE-006’s advancement.
Analyst estimates for Q3 2025 project a loss of $0.27 per share on $12.79 million in revenue, while full-year 2025 expectations stand at a $1.08 loss per share with $59.35 million in sales.
For a deeper dive into Wave Life Sciences’ earnings and future estimates, review the full earnings breakdown here.
Disclaimer: This article is not financial advice. Investors should conduct their own research or consult a financial advisor before making investment decisions.
8.32
+0.14 (+1.71%)
Find more stocks in the Stock Screener